BMN-270 Phase I/II clinical trial by BioMarin Pharmaceutical was started in 2020 and subsequently showed promising preliminary results in the treatment hemophilia A patients with pre-existing immunity to coagulation factor VIII (FVIII) [52]. Here, F8 is linked to hemophilia A.